BiotechTube

VAY736 + lenalidomide

Phase 1Terminated
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Conditions

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Trial Timeline

Jan 24, 2022 โ†’ Feb 24, 2025

NCT ID
NCT04903197

About VAY736 + lenalidomide

VAY736 + lenalidomide is a phase 1 stage product being developed by Novartis for Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04903197. Target conditions include Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04903197Phase 1Terminated

Competing Products

20 competing products in Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

See all competitors
ProductCompanyStageHype Score
YM155 + RituximabAstellas PharmaPhase 2
52
TazemetostatEisaiPhase 2
52
ONTAKEisaiPhase 2
52
TazemetostatEisaiPhase 1
33
ME-401Kyowa KirinPhase 1
33
ME-401Kyowa KirinPhase 2
52
ONO-7018 + ONO-7018Ono PharmaceuticalPhase 1
33
gemcitabineEli LillyPhase 2
52
gemcitabine + cisplatin + dexamethasoneEli LillyPhase 2
52
LY4152199 - IVEli LillyPhase 1
33
LY317615Eli LillyPhase 2
52
LY4584180 + RituximabEli LillyPhase 1
33
PirtobrutinibEli LillyPhase 2
52
Palbociclib + Sunitinib + Temsirolimus + Trastuzumab and Pertuzumab + Vemurafenib and Cobimetinib + Regorafenib + Olaparib + Nivolumab and Ipilimumab + Abemaciclib + Talazoparib + Atezolizumab and Talazoparib + Tucatinib plus Trastuzumab Subcutaneous (SC) + Futibatinib + Dabrafenib plus Trametinib + Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Eli LillyPhase 2
52
Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3
77
HRS-3738Jiangsu Hengrui MedicinePhase 1
33
SHR1459 ๏ผ›YY-20394 + SHR1459 ๏ผ›YY-20394 + Gemcitabine-OxaliplatinJiangsu Hengrui MedicinePhase 2
52
azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8AbbViePhase 1/2
41
Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + LenalidomideAbbViePhase 1/2
41
Siltuximab + EpcoritamabAbbViePhase 1
33

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85